“Biogen is gonna show full data for their anti tau ASO, for the treatment of Alzheimer's. The study missed its primary endpoint, but Biogen is moving into phase three.”
→ Read the source episode
Biogen formally initiates phase three trial(s) for anti-tau ASO in Alzheimer's disease
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.